Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,739 stopped studies mapped to Lymphoma and descendants · 89% state a reason
Over the 1,739 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00183976 | Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related… | Phase 2 | terminated | Sep 16, 2005 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT00183989 | Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma | Phase 2 | terminated | Sep 16, 2005 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT00383565 | FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Phase 2 | terminated | Oct 3, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00608517 | Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD)… | N/A | terminated | Feb 6, 2008 | Vanderbilt-Ingram Cancer Center | slow accrual | Enrollment / accrual |
| NCT01309412 | A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Mar 7, 2011 | Janssen Pharmaceutical K.K. | Protocol was stopped due to the safety issue in Global | Safety / toxicity |
| NCT00293111 | Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory… | Phase 2 | terminated | Feb 17, 2006 | Cephalon | not stated | Not stated |
| NCT00510887 | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular… | Phase 2 | terminated | Aug 2, 2007 | Duke University | Low accrual. | Enrollment / accrual |
| NCT00588822 | Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy… | Phase 2 | terminated | Jan 9, 2008 | Mayo Clinic | Discontinuation due to the high response rate at the 1st stage and slow accrual. | Enrollment / accrual |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00215943 | Phase III Randomized Trial of Thalidomide/Dexamethasone Versus… | Phase 3 | terminated | Sep 22, 2005 | H. Lee Moffitt Cancer Center and Research Institute | Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more effective… | Enrollment / accrual |
| NCT00949117 | Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients… | Phase 2 | terminated | Jul 30, 2009 | University of South Florida | study not feasible with low accrual. DSMB recommended closure | Enrollment / accrual |
| NCT01902862 | An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard… | Phase 2 | terminated | Jul 18, 2013 | Janssen-Cilag G.m.b.H | Recruitment too slow | Enrollment / accrual |
| NCT00863395 | Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma(CTCL) | Phase 1 / Phase 2 | terminated | Mar 18, 2009 | University of Minnesota | not stated | Not stated |
| NCT00441168 | Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin… | Phase 2 | terminated | Feb 28, 2007 | Janssen-Cilag International NV | TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer… | Other (stated, no rule matched) |
| NCT00943293 | Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for… | Phase 1 | terminated | Jul 22, 2009 | University of Chicago | Poor accrual; did not enter phase 2 | Enrollment / accrual |
| NCT00396383 | Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and… | Phase 2 | terminated | Nov 6, 2006 | Genzyme, a Sanofi Company | Insufficient cell mobilization for tandem transplants | Other (stated, no rule matched) |
| NCT00898612 | Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow… | — | withdrawn | May 12, 2009 | Mayo Clinic | No Patients enrolled | Enrollment / accrual |
| NCT00521261 | Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant… | Phase 1 | withdrawn | Aug 27, 2007 | Barbara Ann Karmanos Cancer Institute | not stated | Not stated |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | Phase 1 | terminated | Nov 9, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or… | Phase 1 / Phase 2 | terminated | Jul 11, 2007 | Gilead Sciences | Unacceptable safety profile | Safety / toxicity |
| NCT00590603 | Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple…(AAV) | Phase 1 | terminated | Jan 10, 2008 | Duke University | Poor accrual - terminated during Phase I; Phase II never started. | Enrollment / accrual |
| NCT00308087 | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed…(PREMIER) | Phase 2 | terminated | Mar 29, 2006 | Genzyme, a Sanofi Company | Terminated by sponsor due to low enrollment; see details below | Enrollment / accrual |
| NCT01479023 | Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Nov 24, 2011 | Washington University School of Medicine | treatment was not working | Other (stated, no rule matched) |
| NCT00324831 | GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as… | Phase 3 | suspended | May 11, 2006 | Favrille | not stated | Not stated |
| NCT00818961 | Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer | Phase 2 | terminated | Jan 8, 2009 | Northside Hospital, Inc. | terminated early due to meeting end point with fewer patients than anticipated | Other (stated, no rule matched) |
| NCT00019708 | Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00412919 | Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma | Phase 2 | terminated | Dec 19, 2006 | Bayside Health | Lack of efficacy | Efficacy / futility |
| NCT01090973 | Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell… | Phase 2 | terminated | Mar 23, 2010 | H. Lee Moffitt Cancer Center and Research Institute | Pharmaceutical company request. | Sponsor / business decision |
| NCT00033423 | Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Jan 27, 2003 | University of Alabama at Birmingham | not stated | Not stated |
| NCT00899353 | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) | Phase 2 | terminated | May 12, 2009 | Marshall University | Original Principal Investigator left the institution. | Investigator |
| NCT01854372 | Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC)… | Phase 2 | withdrawn | May 15, 2013 | The University of Texas Health Science Center at San Antonio | not stated | Not stated |
| NCT00361088 | A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma | Phase 1 / Phase 2 | terminated | Aug 7, 2006 | H. Lee Moffitt Cancer Center and Research Institute | Initial Principal Investigator left Moffitt | Investigator |
| NCT00814983 | Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted… | Phase 1 / Phase 2 | terminated | Dec 29, 2008 | Duke University | IND approval for naive T-cell depletion not obtained | Other (stated, no rule matched) |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing… | Phase 2 | terminated | Dec 28, 2011 | Texas Oncology Cancer Center | Insufficient accruals | Enrollment / accrual |
| NCT01355783 | A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the… | Phase 3 | withdrawn | May 18, 2011 | Eisai Inc. | not stated | Not stated |
| NCT00718640 | An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for… | Phase 2 | terminated | Jul 21, 2008 | Janssen-Ortho Inc., Canada | Study stopped due to lagging enrolment. | Enrollment / accrual |
| NCT00058461 | Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or… | Phase 2 | terminated | Apr 9, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00243035 | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | Phase 1 / Phase 2 | terminated | Oct 21, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00176475 | Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Sep 15, 2005 | University of Medicine and Dentistry of New Jersey | slow accrual | Enrollment / accrual |
| NCT00996359 | Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity… | Phase 1 | terminated | Oct 16, 2009 | University of Medicine and Dentistry of New Jersey | Slow accrual | Enrollment / accrual |
| NCT00072449 | Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma | Phase 2 | terminated | Nov 6, 2003 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | slow accrual and lack of resources and priority due to combining 2 consortia | Enrollment / accrual |
| NCT00457574 | Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas | Phase 1 | withdrawn | Apr 6, 2007 | Gemin X | Study terminated prematurely due to financial constraints. | Funding |
| NCT00965861 | SCRI Tissue Testing Registry | — | terminated | Aug 26, 2009 | SCRI Development Innovations, LLC | Replaced by a study with a similar design. | Other (stated, no rule matched) |
| NCT00829205 | Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in… | Phase 1 / Phase 2 | withdrawn | Jan 26, 2009 | Cancer Research UK | not stated | Not stated |
| NCT00947388 | Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | Phase 1 | terminated | Jul 28, 2009 | Case Comprehensive Cancer Center | No more eligible patients | Other (stated, no rule matched) |
| NCT00514722 | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced… | N/A | terminated | Aug 10, 2007 | University of California, San Francisco | low accrual | Enrollment / accrual |
| NCT00241371 | A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma | Phase 2 | terminated | Oct 18, 2005 | Washington University School of Medicine | No response seen in patients | Other (stated, no rule matched) |
| NCT00089115 | Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following… | Phase 3 | terminated | Aug 5, 2004 | Favrille | Withdrawn as company has shut down and filed for bankruptcy | Sponsor / business decision |
| NCT00104819 | Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma | Phase 2 | terminated | Mar 4, 2005 | Favrille | Withdrawn as company has shut down and filed for bankruptcy | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated May 22, 2014source: clinicaltrials